Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
345
resultados
Última actualización
04/11/2026 [08:50:00]
Resumen de: AU2025256964A1
The invention relates to compositions comprising a synergistic combination of memantine and vitamin D, to the method for preparing same and to the use thereof in the prevention and treatment of neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: US20260337275A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US20260335295A1
A compound represented by Formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof according to one aspect can be utilized as a preventive or therapeutic agent and the like for degenerative diseases, such as macular degeneration (AMD), cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), in which HTRA1 activity deficiency is a factor in the aggravation of the diseases, and can be utilized as an adjuvant for efficiently and accurately performing screening of an HTRA activity modulator without temperature changes or the addition of substrates.
Resumen de: WO2026226651A1
Methods of alleviating agitation in a human patient in need thereof, for example, in a human patient having agitation related to Alzheimer's disease, comprising administering to the human patient a first composition comprising xanomeline or a salt thereof and a trospium salt, and administering to the human patient a second composition comprising xanomeline or the salt thereof.
Resumen de: WO2026224659A1
Provided for are diamide PKM2 activators, and pharmaceutical compositions and methods of use thereof for treating PKM2-associated disorders. Further provided for are diamide PKM2 activators, and pharmaceutical compositions and methods of use thereof for treating neurologic and neurodegenerative diseases, including amyotrophic lateral sclerosis. Further provided are diamide PKM2 activators, and pharmaceutical compositions and methods of use thereof for treating peripheral diseases, including fibrotic diseases.
Resumen de: AU2025254772A1
Provided herein are postbiotic compositions prepared using fermentation and herbal substrate compositions for the treatment or prevention of the disruption of the gut-brain axis. Such postbiotic compositions can be used to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Resumen de: AU2025239704A1
This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.
Resumen de: WO2025134150A1
This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators These compounds disrupt the PD-1/PD-L1 checkpoint pathway and may also disrupt one or more related checkpoint pathways. These compounds are useful in treating, preventing or ameliorating disorders such as cancer or infections.
Resumen de: EP4830706A1
0001 The present invention relates to use of a novel compound for preventing, alleviating, or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: WO2025131275A1
The present invention relates to pharmaceutical compositions and medicaments comprising the compound of formula (I); or a stereoisomer, tautomer, pharmaceutically usable solvate or salt thereof, and dosage regimens for the administration thereof to human patients.
Resumen de: WO2025134078A1
The present invention relates to the compounds of formula (I), or an isotopic form, a stereoisomer, or pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The present invention also relates to pharmaceutical compositions comprising such compounds, chemical processes of preparation of such compounds and use of such compounds in the treatment of psychiatric and/or neurological disorders.
Resumen de: EP4830784A2
Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia. Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reelin, or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: EP4831178A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type 1 diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Resumen de: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260327271A1
Recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment are described. The fusion proteins may be administered to patients having a disease or a disorder with the intention of mitigating and/or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and/or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in amyotrophic lateral sclerosis (ALS) patients associated with the condition or disease. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, for example, by a decrease or elimination of symptoms associated with ALS, and/or by a decrease in the duration of such symptoms.
Resumen de: US20260327703A1
0000 The present invention relates to microRNAs for use in diagnostic methods for diagnosing and/or for distinguishing by diagnosis Alzheimer's disease (AD), Frontotemporal Dementia (FTD), and possibly other tauopathies, and/or for measuring therapeutic effect of a treatment of FTD or AD.
Resumen de: US20260325575A1
Provided is a use of borate derivatives in the treatment of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disease. More particularly, the development and administration of pharmaceutical formulations including at least one borate derivative is provided. The borate derivatives are one or a mixture of compounds sodium pentaborate pentahydrate (NaB; NaB5O8·5H2O) or sodium perborate tetrahydrate (SPT; NaBO3·4H2O).
Resumen de: AU2024434669A1
The present invention belongs to the technical field of biomedicine, and relates to a class of dexborneol or fenchyl alcohol ester derivatives of 2-hydroxynicotinic acid, and pharmaceutical uses thereof. The structural general formula of the derivatives is (1), R1 being selected from -H, -Cl, a hydrocarbon group having 1-8 carbon atoms, -CF3, -CF2H, -CN, -SCH3, -OH, -CHO, -CH2OH, -CH2NH2, -COOH, halogenated phenyl, or -NR4R5; R4, R5 are independently selected from -H or -CH3; R2 is selected from -H, an alkyl group having 1-6 carbon atoms, an acyl group having 2-7 carbon atoms, or a carbamoyl group; R 3 is selected from formula (a) or formula (b); X is selected from -CH= or -N=. The derivatives have good inflammation-inhibiting effects, and at high concentrations, they exhibit low cytotoxicity and are safer. The derivatives can be used for preparing a drug for treating inflammation and inflammation-related diseases such as stroke, neuropathic pain, depression and Alzheimer's disease.
Nº publicación: US20260325464A1 22/10/2026
Solicitante:
MAJEED ANJU [IN]
MAJEED SHAHEEN [US]
PANDEY ANJALI [IN]
BANI SARANG [IN]
MAJEED ANJU
MAJEED SHAHEEN
PANDEY ANJALI
BANI SARANG
Resumen de: US20260325464A1
The present invention discloses a composition comprising compounds of Formula I for use in modulating and maintaining water homeostasis in the brain by modulating the expression of aquaporins. More specifically, the invention discloses the use of Gingerenone A in the management of neurodegenerative disorders, specifically Alzheimer's disease and Parkinson's disease by modulating aquaporin expression.
BOPI
Sede Electrónica
